Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

ESMO 2024: Highlights and analysis

ESMO 2024: Latest in EGFR mutated NSCLC

Understanding the use of PARPi combinations to treat patients with mCRPC

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC

Breastfeeding after breast cancer is safe

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Linvoseltamab can be a potentially effective treatment option for patients with relapsed/refractory multiple myeloma

Positive data for the use of radioligand therapy in first-line neuroendocrine cancers